Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

Inclusion Criteria:

• At least 1-year history of migraine with or without aura consistent with a diagnosisaccording to the International Classification of Headache Disorders (ICHD)-3, 2018.

• Prescribed atogepant according to the relevant approved local label.

• For participants who initiate atogepant at the prescribing physician or treatinghealth care provider (HCP) discretion as part of their routine clinical care, thedecision to administer atogepant must be made prior to and independent ofrecruitment into the study.

• Willing and able to comply with the requirements of the study.

• Not on concomitant preventive medication for migraine or have been on a stablepreventive medication for migraine for at least 3 months prior to enrollment in thestudy. If on a stable preventive medication, the prescribing physician or treatingHCP and participant must confirm that there is no plan to change concomitantpreventive medication during the first 12 weeks of the study.

Exclusion Criteria:

• Previously exposed to atogepant as routine therapy or from clinical trialsexperience prior to entry.

• Contraindications to atogepant as per local labeling.

• Pregnant or planning to be pregnant or women of childbearing potential not usingcontraception.

• Enrolled in any interventional studies that may include investigational compoundsfor migraine, or non-AbbVie observational studies.

• In the opinion of the prescribing physician or treating HCP, the participant has ahistory or current evidence of any condition that might interfere with patient'sability to comply with the study requirements.